US20080200449A1 - Treprostinil administration using a metered dose inhaler - Google Patents

Treprostinil administration using a metered dose inhaler Download PDF

Info

Publication number
US20080200449A1
US20080200449A1 US11/748,205 US74820507A US2008200449A1 US 20080200449 A1 US20080200449 A1 US 20080200449A1 US 74820507 A US74820507 A US 74820507A US 2008200449 A1 US2008200449 A1 US 2008200449A1
Authority
US
United States
Prior art keywords
treprostinil
metered dose
dose inhaler
administering
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/748,205
Other languages
English (en)
Inventor
Horst Olschewski
Robert Roscigno
Lewis J. Rubin
Thomas Schmehl
Werner Seeger
Carl Sterritt
Robert Voswinckel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUNG RX Inc A WHOLLY OWNED SUBSIDIARY OF UNITED THERAPEUTICS Corp
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38544006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080200449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US11/748,205 priority Critical patent/US20080200449A1/en
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Assigned to LUNG RX, INC., A WHOLLY OWNED SUBSIDIARY OF UNITED THERAPEUTICS CORPORATION reassignment LUNG RX, INC., A WHOLLY OWNED SUBSIDIARY OF UNITED THERAPEUTICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNITED THERAPEUTICS CORPORATION
Assigned to UNITED THERAPEUTICS CORPORATION reassignment UNITED THERAPEUTICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STERRITT, CARL, ROSCIGNO, ROBERT, RUBIN, LEWIS J.
Assigned to LUNG RX, INC., A WHOLLY OWNED SUBSIDIARY OF UNITED THERAPEUTICS CORPORATION reassignment LUNG RX, INC., A WHOLLY OWNED SUBSIDIARY OF UNITED THERAPEUTICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH
Assigned to TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH reassignment TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHMEHL, THOMAS, VOSWINCKEL, ROBERT, SEEGER, WERNER, OLSCHEWSKI, HORST
Publication of US20080200449A1 publication Critical patent/US20080200449A1/en
Assigned to UNITED THERAPEUTICS CORPORATION reassignment UNITED THERAPEUTICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LUNGRX, A WHOLLY OWNED SUBSIDIARY OF UNITED THERAPEUTICS CORPORATION
Priority to US12/591,200 priority patent/US9358240B2/en
Priority to US13/469,854 priority patent/US9339507B2/en
Priority to US15/011,999 priority patent/US10376525B2/en
Priority to US16/536,954 priority patent/US20190365778A1/en
Priority to US16/778,662 priority patent/US10716793B2/en
Priority to US17/486,721 priority patent/US11357782B2/en
Priority to US17/707,651 priority patent/US20220218720A1/en
Priority to US17/745,333 priority patent/US20220323459A1/en
Priority to US17/967,255 priority patent/US20230062605A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present application relates to methods and kits for therapeutic treatment and, more particularly, to therapeutic methods involving administering treprostinil using a metered dose inhaler and related kits.
  • pulmonary hypertension Generally, pulmonary hypertension is defined through observations of pressures above the normal range pertaining in the majority of people residing at the same altitude and engaged in similar activities.
  • Pulmonary hypertension may occur due to various reasons and the different entities of pulmonary hypertension were classified based on clinical and pathological grounds in 5 categories according to the latest WHO convention, see e.g. Simonneau G., et al. J. Am. Coll. Cardiol. 2004; 43(12 Suppl S):5S-12S.
  • Pulmonary hypertension can be a manifestation of an obvious or explicable increase in resistance, such as obstruction to blood flow by pulmonary emboli, malfunction of the heart's valves or muscle in handling blood after its passage through the lungs, diminution in pulmonary vessel caliber as a reflex response to alveolar hypoxia due to lung diseases or high altitude, or a mismatch of vascular capacity and essential blood flow, such as shunting of blood in congenital abnormalities or surgical removal of lung tissue.
  • certain infectious diseases such as HIV and liver diseases with portal hypertension may cause pulmonary hypertension.
  • Autoimmune disorders such as collagen vascular diseases, also often lead to pulmonary vascular narrowing and contribute to a significant number of pulmonary hypertension patients.
  • idiopathic pulmonary hypertension primary pulmonary hypertension
  • iPAH primary pulmonary hypertension
  • iPAH primary pulmonary hypertension
  • the cases of idiopathic pulmonary arterial hypertension tend to comprise a recognizable entity of about 40% of patients cared for in large specialized pulmonary hypertension centers. Approximately 65% of the most commonly afflicted are female and young adults, though it has occurred in children and patients over 50.
  • Pulmonary hypertension refers to a condition associated with an elevation of pulmonary arterial pressure (PAP) over normal levels. In humans, a typical mean PAP is approximately 12-15 mm Hg. Pulmonary hypertension, on the other hand, can be defined as mean PAP above 25 mmHg, assessed by right heart catheter measurement. Pulmonary arterial pressure may reach systemic pressure levels or even exceed these in severe forms of pulmonary hypertension. When the PAP markedly increases due to pulmonary venous congestion, i.e. in left heart failure or valve dysfunction, plasma can escape from the capillaries into the lung interstitium and alveoli. Fluid buildup in the lung (pulmonary edema) can result, with an associated decrease in lung function that can in some cases be fatal. Pulmonary edema, however, is not a feature of even severe pulmonary hypertension due to pulmonary vascular changes in all other entities of this disease.
  • Pulmonary hypertension may either be acute or chronic.
  • Acute pulmonary hypertension is often a potentially reversible phenomenon generally attributable to constriction of the smooth muscle of the pulmonary blood vessels, which may be triggered by such conditions as hypoxia (as in high-altitude sickness), acidosis, inflammation, or pulmonary embolism.
  • Chronic pulmonary hypertension is characterized by major structural changes in the pulmonary vasculature, which result in a decreased cross-sectional area of the pulmonary blood vessels. This may be caused by, for example, chronic hypoxia, thromboembolism, collagen vascular diseases, pulmonary hypercirculation due to left-to-right shunt, HIV infection, portal hypertension or a combination of genetic mutation and unknown causes as in idiopathic pulmonary arterial hypertension.
  • Pulmonary hypertension has been implicated in several life-threatening clinical conditions, such as adult respiratory distress syndrome (“ARDS”) and persistent pulmonary hypertension of the newborn (“PPHN”).
  • ARDS adult respiratory distress syndrome
  • PPHN persistent pulmonary hypertension of the newborn
  • Zapol et al. Acute Respiratory Failure, p. 241-273, Marcel Dekker, New York (1985); Peckham, J. Ped. 93:1005 (1978).
  • PPHN a disorder that primarily affects full-term infants, is characterized by elevated pulmonary vascular resistance, pulmonary arterial hypertension, and right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale of the newborn's heart.
  • Mortality rates range from 12-50%.
  • Pulmonary hypertension may also ultimately result in a potentially fatal heart condition known as “cor pulmonale,” or pulmonary heart disease.
  • cor pulmonale or pulmonary heart disease.
  • One embodiment is a method of delivering to a subject in need thereof a therapeutically effective amount of treprostinil, or treprostinil derivative or a pharmaceutically acceptable salt thereof comprising administering to the subject a therapeutically effective amount of the treprostinil or treprostinil derivative or a pharmaceutically acceptable salt thereof using a metered dose inhaler.
  • Another embodiment is a method for treating pulmonary hypertension comprising administering to a subject in need thereof treprostinil or its derivative, or a pharmaceutically acceptable salt thereof using a metered dose inhaler.
  • kits comprising a metered dose inhaler containing a pharmaceutical formulation comprising treprostinil or treprostinil derivative, or a pharmaceutically acceptable salt thereof.
  • kits for treating pulmonary hypertension in a subject comprising (i) an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, (ii) a metered dose inhaler; (iii) instructions for use in treating pulmonary hypertension.
  • Administration of treprostinil using a metered dose inhaler can provide patients, such as pulmonary hypertension patients, with a high degree of autonomy.
  • FIG. 1 pulmonary and systemic changes in hemodynamics following the inhalation of placebo (open circles), 30 ⁇ g treprostinil (triangles), 45 ⁇ g treprostinil (squares) or 60 ⁇ g TREprostinil (black circles) applied by a Metered Dose Inhaler (MDI-TRE).
  • MDI-TRE Metered Dose Inhaler
  • a single short inhalation of treprostinil induced sustained reduction of PAP and PVR that outlasted the observation period of 120 minutes at doses of 45 and 60 ⁇ g MDI-TRE.
  • Systemic arterial pressure and resistance were not significantly affected.
  • PAP mean pulmonary artery pressure
  • PVR pulmonary vascular resistance
  • SAP mean systemic arterial pressure
  • SVR systemic vascular resistance.
  • Data are given as mean value ⁇ standard error of the mean (SEM).
  • FIG. 2 presents hemodynamic changes induced by the inhalation of placebo (open circles), 30 ⁇ g treprostinil (triangles), 45 ⁇ g treprostinil (squares) or 60 ⁇ g treprostinil (black circles) applied by a metered dose inhaler.
  • Treprostinil induced sustained elevation of cardiac output.
  • Heart rate was rather unchanged as a sign for low spillover of MDI-TRE to the systemic circulation. Gas exchange was not negatively affected.
  • CO cardiac output
  • HR heart rate
  • SaO2 arterial oxygen saturation
  • SvO2 central venous oxygen saturation.
  • Data are given as mean value ⁇ SEM.
  • FIG. 3 shows areas under the curve for changes in pulmonary vascular resistance (PVR) calculated for an observation period of 120 minutes after inhalation treprostinil using a metered dose inhaler. PVR was markedly lowered by treprostinil inhalation. The increased pulmonary vasodilation over time with the two highest doses mainly relies on the more sustained effect over time. Data are shown as mean value ⁇ 95% confidence intervals.
  • PVR pulmonary vascular resistance
  • FIG. 4 demonstrates Ventilation-perfusion matching measured with the multiple inert gas elimination technique.
  • NO nitric oxide
  • MDI-TRE metered dose inhaler
  • FIG. 5 presents response of pulmonary vascular resistance (PVR) to inhaled treprostinil vs. iloprost—period effects.
  • PVR pulmonary vascular resistance
  • FIG. 6 presents response of PVR and systemic arterial pressure (SAP) to inhalation of treprostinil vs. iloprost—dose effects.
  • a) Inhalation of 7.5 ⁇ g iloprost (in 6 min) vs. 7.5 ⁇ g treprostinil (6 min) (n 14, in a randomized order).
  • b) Inhalation of 7.5 ⁇ g iloprost (6 min) vs. 15 ⁇ g treprostinil (6 min) (n 14, in randomized order).
  • c) Inhalation of 7.5 ⁇ g iloprost (6 min) vs. 15 ⁇ g treprostinil (3 min) (n 16, in randomized order).
  • Data are shown as percent of baseline values (mean ⁇ 95% confidence interval). Iloprost, filled circles; Treprostinil, open triangles.
  • FIG. 7 presents hemodynamic response to inhalation of treprostinil vs. iloprost.
  • Data from n 44 patients, who inhaled both drugs in randomized order, shown as percent of baseline values (mean value ⁇ 95% confidence interval).
  • PVR pulmonary vascular resistance
  • PAP mean pulmonary arterial pressure
  • SAP mean systemic arterial pressure
  • CO cardiac output.
  • FIG. 8 presents pharmacodynamics after treprostinil inhalation vs. placebo.
  • Placebo or treprostinil in doses of 30 ⁇ g, 60 ⁇ g or 90 ⁇ g were inhaled (means ⁇ 95% confidence intervals). Maximal decrease of PVR was comparable for all doses. The duration of pulmonary vasodilation (PVR-decrease) appeared to be dose dependent.
  • PVR pulmonary vascular resistance
  • PAP mean pulmonary arterial pressure
  • SAP mean systemic arterial pressure
  • CO cardiac output
  • SaO2 arterial oxygen saturation
  • SvO2 mixed venous oxygen saturation.
  • FIG. 9 presents Areas Between the placebo and the treprostinil Curves (ABC). ABCs were calculated for a 3-hour period after inhalation of TRE or placebo from the relative changes of hemodynamic parameters (means ⁇ 95% confidence intervals).
  • PVR pulmonary vascular resistance
  • PAP mean pulmonary arterial pressure
  • SAP mean systemic arterial pressure
  • SVR systemic vascular resistance.
  • FIG. 10 presents hemodynamic responses to the inhalation of 15 ⁇ g treprostinil.
  • the inhalation time by increasing treprostinil concentration.
  • a pulse of aerosol was generated every 6 seconds.
  • Placebo data correspond to FIG. 8 .
  • Data are shown as means ⁇ 95% confidence intervals.
  • PVR pulmonary vascular resistance
  • PAP mean pulmonary arterial pressure
  • SAP mean systemic arterial pressure
  • CO cardiac output.
  • FIG. 11 presents areas between the placebo curve and the responses to 15 ⁇ g treprostinil applied at increasing concentrations to minimize inhalation time.
  • Mean ⁇ SEM of relative changes of hemodynamic parameters observation time 120 min.
  • PAP pulmonary arterial pressure
  • SAP systemic arterial pressure
  • PVR pulmonary vascular resistance
  • CO cardiac output
  • SaO2 systemic arterial oxygen saturation
  • SvO2 pulmonary arterial oxygen saturation.
  • FIG. 12 presents pharmacokinetics of treprostinil after a single inhalation.
  • Data with error bars represent mean values ⁇ SEM.
  • treprostinil can be administered in a few single inhalations using a compact inhalation device, such as a metered dose inhaler. Furthermore, the inventors discovered that such administering does not cause significant side effects, especially no significant side effects related to systemic blood pressure and circulation as well as no gas exchange deteriorations or disruptions.
  • one embodiment of the invention is a method of delivering to a subject in need thereof, such as a human being, a therapeutically effective amount of treprostinil comprising administering to the subject a formulation comprising a therapeutically effective amount of treprostinil, its derivative or a pharmaceutically acceptable salt thereof using a metered dose inhaler.
  • Treprostinil can be administered via a metered dose inhaler to a subject affected with a condition or disease, which can be treated by treprostinil, such as asthma, pulmonary hypertension, peripheral vascular disease or pulmonary fibrosis.
  • Another embodiment of the invention is a method for treating pulmonary hypertension, comprising administering to a subject in need thereof, such as a human being, treprostinil or its derivative, or a pharmaceutically acceptable salt using a metered dose inhaler.
  • Treprostinil or 9-deoxy-2′,9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F1 is a prostacyclin analogue, first described in U.S. Pat. No. 4,306,075.
  • U.S. Pat. No. 5,153,222 describes use of treprostinil for treatment of pulmonary hypertension.
  • Treprostinil is approved for the intravenous as well as subcutaneous route, the latter avoiding septic events associated with continuous intravenous catheters.
  • 6,521,212 and 6,756,033 describe administration of treprostinil by inhalation for treatment of pulmonary hypertension, peripheral vascular disease and other diseases and conditions.
  • U.S. Pat. No. 6,803,386 discloses administration of treprostinil for treating cancer such as lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancer.
  • US patent application publication No. 2005/0165111 discloses treprostinil treatment of ischemic lesions.
  • U.S. Pat. No. 7,199,157 discloses that treprostinil treatment improves kidney functions.
  • US patent application publication No. 2005/0282903 discloses treprostinil treatment of neuropathic foot ulcers.
  • U.S. provisional application No. 60/900,320 filed Feb. 9, 2007, discloses treprostinil treatment of pulmonary fibrosis.
  • acid derivative is used herein to describe C1-4 alkyl esters and amides, including amides wherein the nitrogen is optionally substituted by one or two C1-4 alkyl groups.
  • the present invention also encompasses methods of using Treprostinil or its derivatives, or pharmaceutically acceptable salts thereof.
  • a method uses Treprostinil sodium, currently marketed under the trade name of REMODULIN®.
  • the FDA has approved Treprostinil sodium for the treatment of pulmonary arterial hypertension by injection of dose concentrations of 1.0 mg/mL, 2.5 mg/mL, 5.0 mg/mL and 10.0 mg/mL.
  • the chemical structure formula for Treprostinil sodium is:
  • Treprostinil sodium is sometimes designated by the chemical names: (a) [(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid; or (b) 9-deoxy-2′,9- ⁇ -methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F 1 .
  • Treprostinil sodium is also known as: UT-15; LRX-15; 15AU81; UNIPROSTTM; BW A15AU; and U-62,840.
  • the molecular weight of Treprostinil sodium is 390.52, and its empirical formula is C 23 H 34 O 5 .
  • treprostinil can be administered in combination with one or more additional active agents.
  • such one or more additional active agents can be also administered together with treprostinil using a metered dose inhaler.
  • such one or more additional active agents can be administered separately from treprostinil.
  • Particular additional active agents that can be administered in combination with treprostinil may depend on a particular disease or condition for treatment or prevention of which treprostinil is administered.
  • the additional active agent can be a cardiovascular agent such as a calcium channel blocker, a phosphodiesterase inhibitor, an endothelial antagonist, or an antiplatelet agent.
  • the present invention extends to methods of using physiologically acceptable salts of Treprostinil, as well as non-physiologically acceptable salts of Treprostinil that may be used in the preparation of the pharmacologically active compounds of the invention.
  • salts of inorganic bases can be, for example, salts of alkali metals such as sodium or potassium; alkaline earth metals such as calcium and magnesium or aluminum; and ammonia.
  • Salts of organic bases can be, for example, salts trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, and triethanolamine.
  • Salts of inorganic acids can be, for example, salts of hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid.
  • Salts of organic acids can be, for example, salts of formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, lactic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
  • Salts of basic amino acids can be, for example, salts of arginine, lysine and ornithine.
  • Salts of acidic amino acids can include, for example, salts of aspartic acid and glutamic acid.
  • Quaternary ammonium salts can be formed, for example, by reaction with lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides, with dialkyl sulphates, with long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides, and with aralkyl halides, such as benzyl and phenethyl bromides.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides
  • dialkyl sulphates with long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides
  • aralkyl halides such as benzyl and phenethy
  • Preferred pharmaceutically acceptable salts are disclosed, for example, in US patent application publication No. 20050085540.
  • Treprostinil can be administered by inhalation, which in the present context refers to the delivery of the active ingredient or a combination of active ingredients through a respiratory passage, wherein the subject in need of the active ingredient(s) through the subject's airways, such as the subject's nose or mouth.
  • a metered dose inhaler in the present context means a device capable of delivering a metered or bolus dose of respiratory drug, such as treprostinil, to the lungs.
  • a metered or bolus dose of respiratory drug such as treprostinil
  • the inhalation device can be a pressurized metered dose inhaler, a device which produces the aerosol clouds for inhalation from solutions and/or suspensions of respiratory drugs in chlorofluorocarbon (CFC) and/or hydrofluoroalkane (HFA) solutions.
  • CFC chlorofluorocarbon
  • HFA hydrofluoroalkane
  • the inhalation device can be also a dry powder inhaler.
  • the respiratory drug is inhaled in solid formulation, usually in the form of a powder with particle size less than 10 micrometers in diameter or less than 5 micrometers in diameter.
  • the metered dose inhaler can be a soft mist inhaler (SMI), in which the aerosol cloud containing a respiratory drug can be generated by passing a solution containing the respiratory drug through a nozzle or series of nozzles.
  • SMI soft mist inhaler
  • Examples of soft mist inhalers include the Respimat® Inhaler (Boeringer Ingelheim GmbH), the AERx® Inhaler (Aradigm Corp.), the MysticTM Inhaler (Ventaira Pharmaceuticals, Inc) and the AiraTM Inhaler (Chrysalis Technologies Incorporated).
  • SMI soft mist inhaler
  • the aerosol cloud containing a respiratory drug can be generated by passing a solution containing the respiratory drug through a nozzle or series of nozzles.
  • the aerosol generation can be achieved in SMI, for example, by mechanical, electromechanical or thermomechanical process.
  • Examples of soft mist inhalers include the Respimat® Inhaler (Boeringer Ingelheim GmbH), the A
  • the aerosol for SMI can be generated from a solution of the respiratory drug further containing pharmaceutically acceptable excipients.
  • the respiratory drug is treprostinil, its derivative or a pharmaceutically acceptable salt thereof, which can be formulated in SMI is as a solution.
  • the solution can be, for example, a solution of treprostinil in water, ethanol or a mixture thereof.
  • the diameter of the treprostinil-containing aerosol particles is less than about 10 microns, or less than about 5 microns, or less than about 4 microns.
  • Treprostinil concentration in an aerosolable formulation, such as a solution, used in a metered dose inhaler can range from about 500 ⁇ g/ml to about 2500 ⁇ g/ml, or from about 800 ⁇ g/ml to about 2200 ⁇ g/ml, or from about 1000 ⁇ g/ml to about 2000 ⁇ g/ml.
  • the dose of treprostinil that can be administered using a metered dose inhaler in a single event can be from about 15 ⁇ g to about 100 ⁇ g or from about 15 ⁇ g to about 90 ⁇ g or from about 30 ⁇ g to about 90 ⁇ g or from about 30 ⁇ g to about 60 ⁇ g.
  • Administering of treprostinil in a single event can be carried out in a limited number of breaths by a patient.
  • treprostinil can be administered in 20 breaths or less, or in 10 breaths or less, or than 5 breaths or less.
  • treprostinil is administered in 3, 2 or 1 breaths.
  • the total time of a single administering event can be less than 5 minutes, or less than 1 minute, or less than 30 seconds.
  • Treprostinil can be administered a single time per day or several times per day.
  • the method of treatment of pulmonary hypertension can further comprise administering at least one supplementary agent selected from the group consisting of sildenafil, tadalafil, calcium channel blockers (diltiazem, amlodipine, nifedipine), bosentan, sitaxsentan, ambrisentan, and pharmaceutically acceptable salts thereof.
  • the supplementary agents can be included in the treprostinil formulation and, thus, can be administered simultaneously with treprostinil using a metered dose inhaler.
  • the supplementary agents can be administered separately from treprostinil.
  • the application of intravenous prostacyclin (flolan), intravenous iloprost or intravenous or subcutaneous treprostinil can be administered in addition to treprostinil administered via inhalation using a metered dose inhaler.
  • the present invention also provides a kit that includes a metered dose inhaler containing a pharmaceutical formulation comprising treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
  • a kit can further include instructions on how to use the metered dose inhaler for inhaling treprostinil.
  • Such instructions can include, for example, information on how to coordinate patient's breathing, and actuation of the inhaler.
  • the kit can be used by a subject, such as human being, affected with a disease or condition that can be treated by treprostinil, such as asthma, pulmonary hypertension, peripheral vascular disease or pulmonary fibrosis.
  • the kit is a kit for treating pulmonary hypertension, that includes (i) a metered dose inhaler containing a pharmaceutical formulation comprising treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, and (ii) instructions for use of the metered dose inhaler containing treprostinil in treating pulmonary hypertension.
  • instructions for use shall mean any FDA-mandated labeling, instructions, or package inserts that relate to the administration of Treprostinil or its derivatives, or pharmaceutically acceptable salts thereof, for treatment of pulmonary hypertension by inhalation.
  • instructions for use may include, but are not limited to, indications for pulmonary hypertension, identification of specific symptoms associated with pulmonary hypertension, that can be ameliorated by Treprostinil, recommended dosage amounts for subjects suffering from pulmonary hypertension and instructions on coordination of individual's breathing and actuation of the metered dose inhaler.
  • SMI-TRE soft mist inhaler
  • TRE doses of 30 ⁇ g, 45 ⁇ g and 60 ⁇ g reduced pulmonary vascular resistance (PVR) to 84.4 ⁇ 8.7%, 71.4 ⁇ 17.5% and 77.5 ⁇ 7.2% of baseline values, respectively (mean ⁇ 95% confidence interval).
  • the 120 minute area under the curve for PVR for placebo, 30 ⁇ g, 45 ⁇ g and 60 ⁇ g TRE was 1230 ⁇ 1310, ⁇ 870 ⁇ 940, ⁇ 2450 ⁇ 2070 and ⁇ 2000 ⁇ 900 min %, respectively.
  • Reduction of PVR by a single inhalation of the two higher doses outlasted the observation period of 120 minutes. Reduction of systemic vascular resistance and pressure was negligible, showing a high pulmonary selectivity for SMI-TRE.
  • Intrapulmonary selectivity was also provided by SMI-TRE as ventilation/perfusion matching, assessed by the multiple inert gas elimination technique in 5 patients with gas exchange problems, was not significantly different after SMI-TRE compared to inhaled nitric oxide or no treatment. No significant side effects were observed.
  • a total number of 45 patients with moderate to severe precapillary pulmonary hypertension were enrolled.
  • PAP pulmonary artery pressure
  • PVR pulmonary vascular resistance
  • PAWP pulmonary artery wedge pressure
  • CO central venous pressure
  • SvO2 central venous oxygen saturation
  • iPAH idiopathic PAH
  • CTEPH chronic thromboembolic pulmonary hypertension
  • the aerosol sizes before (placebo) and after filling (treprostinil) were unchanged.
  • the aerosol particles mass median aerodynamic diameter of treprostinil-aerosol was 4-5 ⁇ m, which can be at the upper limit for alveolar deposition.
  • the aerosol volume delivered by one cycle from the SMI was 15 ⁇ l.
  • the solution used for aerosol generation was prepared from treprostinil sodium salt using a standard protocol.
  • the different doses were applied as 2 puffs 1000 ⁇ g/ml (30 ⁇ g), 3 puffs 1000 ⁇ g/ml (45 ⁇ g) and 2 puffs 2000 ⁇ g/ml (60 ⁇ g).
  • the placebo was inhaled as 2 puffs from a placebo-SMI. Hemodynamics and gas-exchange parameters were recorded for 120 minutes after TRE inhalation. This study used the Respimat® device, because the implemented “soft mist” technology was well suited for the deposition of such highly active drugs like prostanoids.
  • treprostinil sodium from the metered dose inhaler was well tolerated, only mild and transient cough for a maximum of one minute was reported. No systemic side effects like headache, flush, nausea or dizziness were observed.
  • PAP pulmonary artery pressure
  • PVR pulmonary vascular resistance
  • SVR systemic vascular resistance
  • CO cardiac output
  • SAP systemic arterial pressure
  • HR heart rate
  • SaO2 arterial oxygen saturation
  • SvO2 central venous oxygen saturation.
  • the areas under the curve for PVR were calculated for placebo and the different SMI-TRE doses over the 120 minute observation period ( FIG. 3 ).
  • a dose effect of SMI-TRE with a trend to a more sustained effect with the two highest doses could be observed.
  • the inhalation of a highly concentrated aerosol can be in theory prone to disturbances of gas exchange because the deposition of even small amounts of aerosol may deliver high doses locally and thereby antagonize the hypoxic pulmonary vasoconstriction in poorly ventilated areas. This would then lead to increased shunt flow or increase of low ventilation/perfusion (V/Q) areas.
  • MIGET multiple inert gas elimination technique
  • the MIGET patients were selected for pre-existing gas exchange limitations. Characteristics of these patients were: PAP 54.6 ⁇ 3.2 mmHg, PVR 892 ⁇ 88 dynes, SaO2 91.7 ⁇ 0.5%, SvO2 65.2 ⁇ 1.8%.
  • the maximal relative reduction of SaO2 after inhalation of SMI-TRE in these patients was ⁇ 3.8 ⁇ 1.5% compared to baseline values.
  • Shunt flow at baseline, NO-inhalation and 60 minutes after SMI-TRE was 6.4 ⁇ 4.3%, 5.4 ⁇ 3.0% and 8.3 ⁇ 3.4%, respectively (mean ⁇ 95% confidence interval; FIG. 4 ).
  • Treprostinil is tolerated at high doses with no systemic side effects.
  • the application of an effective amount of treprostinil in only few or even one single breath was achieved with a highly concentrated treprostinil sodium solution.
  • Treprostinil can be applied by a metered dose inhaler, such as Respimat® soft mist inhaler.
  • the mean pulmonary artery pressure of the enrolled patients was about 50 mmHg. Hemodynamics and patient characteristics were similar in all studies.
  • TRE and Iloprost (ILO) at an inhaled dose of 7.5 ⁇ g, displayed comparable PVR decrease, with a significantly different time course (p ⁇ 0.001), TRE exhibiting a more sustained effect on PVR (p ⁇ 0.0001) and less systemic side effects.
  • placebo 30 ⁇ g, 60 ⁇ g, 90 ⁇ g or 120 ⁇ g TRE were applied with drug effects being observed for 3 hours after inhalation. A near-maximal acute PVR decrease was observed at 30 ⁇ g TRE.
  • TRE was inhaled with a pulsed ultrasonic nebulizer, mimicking a metered dose inhaler.
  • 15 ⁇ g TRE was inhaled with 18 pulses (TRE concentration 100 ⁇ g/ml), 9 pulses (200 ⁇ g/ml), 3 pulses (600 ⁇ g/ml), 2 pulses (1000 ⁇ g/ml) or 1 pulse (2000 ⁇ g/ml), each mode achieving comparable, sustained pulmonary vasodilation.
  • Inhaled treprostinil exerts sustained pulmonary vasodilation with excellent tolerability at doses, which may be inhaled in a few or even one breath.
  • Inhaled treprostinil is advantageous to inhaled iloprost in terms of duration of effect and systemic side effects.
  • Inhaled treprostinil is well tolerated in concentrations up to 2000 mg/ml (bringing down inhalation time to a single breath) and in high doses (up to 90 ⁇ g).
  • Study i was a randomized, open-label, single-blind crossover study. The primary objective was to compare the acute hemodynamic effects and the systemic side effects of inhaled treprostinil with inhaled iloprost at comparable doses. A total number of 44 patients with moderate to severe precapillary pulmonary hypertension were enrolled. Patient characteristics and hemodynamic as well as gas exchange parameters are outlined in Table 3.
  • a 7.5 g ILO vs. 7.5 ⁇ g TRE
  • b 7.5 g ILO vs. 15 ⁇ g TRE (6 min inhalation time)
  • c 7.5 g ILO vs. 15 ⁇ g TRE (3 min inhalation time).
  • Group 2 corresponds to study ii); evaluation of maximal tolerated dose of TRE.
  • a placebo inhalation
  • b 30 ⁇ g TRE
  • c 60 ⁇ g TRE
  • d 90 ⁇ g TRE
  • e 120 ⁇ g TRE.
  • Group 3 corresponds to study iii); reduction of inhalation time by increase of TRE concentration, aiming at a total inhaled dose of 15 ⁇ g.
  • Etiology of pulmonary hypertension was classified as idiopathic PAH (i), PAH of other causes (o), chronic thromboembolic PH (t), and pulmonary fibrosis (f).
  • this corresponds to a total inhaled dose of 7.5 ⁇ g iloprost and treprostinil (4 ⁇ g/ml) and 15 ⁇ g treprostinil (8 ⁇ g/ml and 16 ⁇ g/ml), respectively.
  • Study ii) was a randomized, open-label, single blind, placebo controlled study.
  • the primary objectives were to describe the pharmacodynamic and pharmacokinetic effects of inhaled treprostinil at a well tolerated dose (30 ⁇ g) and to explore the highest tolerated single dose.
  • Study iii) was a randomized, open-label, single blind study. The primary objective was to explore the shortest possible inhalation time for a 15 ⁇ g dose of inhaled treprostinil. A total of 48 patients inhaled one dose of TRE during right heart catheter investigation. The drug was applied in 18, 9, 3, 2 or 1 breaths.
  • the aerosol was generated by a pulsed ultrasonic nebulizer (Ventaneb, Nebutec, Elsenfeld, Germany) in cycles consisting of 2 seconds aerosol production (pulse) and 4 seconds pause.
  • the device included an opto-acoustical trigger for the patient to synchronize the inspiration to the end of the aerosol pulse, thereby providing exact dosage.
  • Treprostinil plasma concentrations were assessed in study ii) at 10, 15, 30, 60 and 120 minutes after inhalation.
  • Treprostinil quantification was done by Alta Analytical Laboratory (El Dorado Hills, Calif., USA) with a validated liquid chromatography atmospheric-pressure ionization tandem mass spectrometry as previously described Wade M., et al. J. Clin. Pharmacol. 2004;44:503-9.
  • Mixed venous blood was drawn at the depicted time points ( FIG. 11 ) after inhalation, centrifuged and the plasma frozen at ⁇ 80° C. until temperature controlled shipping on dry ice.
  • FIG. 7 An overview of the pooled data of treprostinil inhalation as compared to iloprost inhalation is given in FIG. 7 .
  • the maximum effect of iloprost and treprostinil on PVR was comparable but this effect was reached significantly later after treprostinil inhalation (18 ⁇ 2 min) compared to iloprost (8 ⁇ 1 min; mean ⁇ SEM, p ⁇ 0.0001) and lasted considerably longer (after 60 min, PVR values in the treprostinil group had not yet returned to baseline).
  • the increase in cardiac output was less acute but prolonged after treprostinil inhalation.
  • SAP Systemic arterial pressure
  • PAP was reduced to 84.2 ⁇ 4.5% (18 pulses, 100 ⁇ g/ml), 84.2 ⁇ 4.1% (9 pulses, 200 ⁇ g/ml), 81.1 ⁇ 4.1% (3 pulses, 600 ⁇ g/ml), 86 ⁇ 4% (2 pulses, 1000 ⁇ g/ml) and 88 ⁇ 5.4% (1 pulse, 2000 ⁇ g/ml). Cardiac output was moderately increased in all groups, whereas systemic arterial pressure was not significantly affected.
  • This study used a cross-over design in order to minimize the effects of inter-individual differences in response to prostanoids.
  • the short observation period of 1 hour was used to avoid an uncomfortably long catheter investigation.
  • the short observation interval may have caused carryover effects of the first to the second period as suggested by FIG. 5 .
  • both drugs are potent pulmonary vasodilators and that treprostinil effects are significantly sustained compared to the iloprost effects.
  • Inhaled treprostinil can be applied in high doses (up to 90 ⁇ g) with a minimal inhalation time. Inhaled treprostinil exerts high pulmonary selectivity and leads to a long-lasting pulmonary vasodilation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/748,205 2006-05-15 2007-05-14 Treprostinil administration using a metered dose inhaler Abandoned US20080200449A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US11/748,205 US20080200449A1 (en) 2006-05-15 2007-05-14 Treprostinil administration using a metered dose inhaler
US12/591,200 US9358240B2 (en) 2006-05-15 2009-11-12 Treprostinil administration by inhalation
US13/469,854 US9339507B2 (en) 2006-05-15 2012-05-11 Treprostinil administration by inhalation
US15/011,999 US10376525B2 (en) 2006-05-15 2016-02-01 Treprostinil administration by inhalation
US16/536,954 US20190365778A1 (en) 2006-05-15 2019-08-09 Treprostinil administration by inhalation
US16/778,662 US10716793B2 (en) 2006-05-15 2020-01-31 Treprostinil administration by inhalation
US17/486,721 US11357782B2 (en) 2006-05-15 2021-09-27 Treprostinil administration by inhalation
US17/707,651 US20220218720A1 (en) 2006-05-15 2022-03-29 Treprostinil administration by inhalation
US17/745,333 US20220323459A1 (en) 2006-05-15 2022-05-16 Treprostinil administration by inhalation
US17/967,255 US20230062605A1 (en) 2006-05-15 2022-10-17 Treprostinil administration by inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80001606P 2006-05-15 2006-05-15
US11/748,205 US20080200449A1 (en) 2006-05-15 2007-05-14 Treprostinil administration using a metered dose inhaler

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/591,200 Continuation US9358240B2 (en) 2006-05-15 2009-11-12 Treprostinil administration by inhalation

Publications (1)

Publication Number Publication Date
US20080200449A1 true US20080200449A1 (en) 2008-08-21

Family

ID=38544006

Family Applications (10)

Application Number Title Priority Date Filing Date
US11/748,205 Abandoned US20080200449A1 (en) 2006-05-15 2007-05-14 Treprostinil administration using a metered dose inhaler
US12/591,200 Active 2028-05-05 US9358240B2 (en) 2006-05-15 2009-11-12 Treprostinil administration by inhalation
US13/469,854 Active 2028-03-10 US9339507B2 (en) 2006-05-15 2012-05-11 Treprostinil administration by inhalation
US15/011,999 Active US10376525B2 (en) 2006-05-15 2016-02-01 Treprostinil administration by inhalation
US16/536,954 Abandoned US20190365778A1 (en) 2006-05-15 2019-08-09 Treprostinil administration by inhalation
US16/778,662 Active US10716793B2 (en) 2006-05-15 2020-01-31 Treprostinil administration by inhalation
US17/486,721 Active US11357782B2 (en) 2006-05-15 2021-09-27 Treprostinil administration by inhalation
US17/707,651 Pending US20220218720A1 (en) 2006-05-15 2022-03-29 Treprostinil administration by inhalation
US17/745,333 Pending US20220323459A1 (en) 2006-05-15 2022-05-16 Treprostinil administration by inhalation
US17/967,255 Pending US20230062605A1 (en) 2006-05-15 2022-10-17 Treprostinil administration by inhalation

Family Applications After (9)

Application Number Title Priority Date Filing Date
US12/591,200 Active 2028-05-05 US9358240B2 (en) 2006-05-15 2009-11-12 Treprostinil administration by inhalation
US13/469,854 Active 2028-03-10 US9339507B2 (en) 2006-05-15 2012-05-11 Treprostinil administration by inhalation
US15/011,999 Active US10376525B2 (en) 2006-05-15 2016-02-01 Treprostinil administration by inhalation
US16/536,954 Abandoned US20190365778A1 (en) 2006-05-15 2019-08-09 Treprostinil administration by inhalation
US16/778,662 Active US10716793B2 (en) 2006-05-15 2020-01-31 Treprostinil administration by inhalation
US17/486,721 Active US11357782B2 (en) 2006-05-15 2021-09-27 Treprostinil administration by inhalation
US17/707,651 Pending US20220218720A1 (en) 2006-05-15 2022-03-29 Treprostinil administration by inhalation
US17/745,333 Pending US20220323459A1 (en) 2006-05-15 2022-05-16 Treprostinil administration by inhalation
US17/967,255 Pending US20230062605A1 (en) 2006-05-15 2022-10-17 Treprostinil administration by inhalation

Country Status (8)

Country Link
US (10) US20080200449A1 (fr)
EP (1) EP2026816B1 (fr)
JP (4) JP5797376B2 (fr)
KR (1) KR101390579B1 (fr)
CN (1) CN101495122B (fr)
CA (1) CA2654492C (fr)
ES (1) ES2707548T3 (fr)
WO (1) WO2007134292A2 (fr)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163738A1 (en) * 2007-12-17 2009-06-25 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin
US20090281189A1 (en) * 2008-05-08 2009-11-12 United Therepeutics Corporation Treprostinil formulation
US20100076083A1 (en) * 2006-05-15 2010-03-25 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20100282622A1 (en) * 2009-05-07 2010-11-11 United Therapeutics Corporation Solid formulations of prostacyclin analogs
US20110092599A1 (en) * 2004-04-12 2011-04-21 United Therapeutics Corporation Use of Treprostinil to treat neuropathic diabetic foot ulcers
WO2011153363A1 (fr) 2010-06-03 2011-12-08 United Therapeutics Corporation Production de tréprostinil
US20120177693A1 (en) * 2008-09-25 2012-07-12 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
US8461393B2 (en) 2011-03-02 2013-06-11 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
WO2013104317A1 (fr) 2012-01-10 2013-07-18 上海天伟生物制药有限公司 Forme cristalline d'un analogue de prostaglandine, son procédé de préparation et son utilisation
WO2013104318A1 (fr) 2012-01-10 2013-07-18 上海天伟生物制药有限公司 Forme cristalline d'un analogue de prostaglandine, son procédé de préparation et son utilisation
US8609728B2 (en) 2010-03-15 2013-12-17 United Therapeutics Corporation Treatment for pulmonary hypertension
WO2015061720A2 (fr) 2013-10-25 2015-04-30 Insmed Incorporated Composés de prostacycline, compositions en contenant et leurs procédés d'utilisation
US9102660B2 (en) 2013-03-25 2015-08-11 United Therapeutics Corporaiton Process of making prostacyclin compounds with linker thiol and pegylated forms
US9155846B2 (en) 2006-06-07 2015-10-13 United Therapeutics Corporation Dosage inhaler
WO2015192030A1 (fr) 2014-06-13 2015-12-17 United Therapeutics Corporation Formulations de tréprostinil
WO2016064764A1 (fr) 2014-10-20 2016-04-28 United Therapeutics Corporation Synthèse d'intermédiaire pour la production de dérivés de prostacycline
WO2016088119A1 (fr) 2014-12-03 2016-06-09 Steadymed Ltd Formulations de tréprostinil exemptes de conservateur et procédés et dispositifs s'utilisant avec celles-ci
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9701611B2 (en) 2013-03-15 2017-07-11 United Therapeutics Corporation Salts of treprostinil
US9822057B2 (en) 2013-03-14 2017-11-21 United Therapeutics Corporation Solid forms of treprostinil
WO2018058124A1 (fr) 2016-09-26 2018-03-29 United Therapeutics Corporation Promédicaments de tréprostinil
US20190151332A1 (en) * 2016-05-05 2019-05-23 Liquidia Technologies, Inc. Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US10413513B2 (en) 2013-07-18 2019-09-17 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US20190321290A1 (en) * 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
US10772883B2 (en) 2009-06-12 2020-09-15 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
WO2021041320A1 (fr) 2019-08-23 2021-03-04 United Therapeutics Corporation Promédicaments de tréprostinil
US20210146071A1 (en) * 2016-01-29 2021-05-20 Mannkind Corporation Dry powder inhaler
WO2021211916A1 (fr) 2020-04-17 2021-10-21 United Therapeutics Corporation Tréprostinil destiné à être utilisé dans le traitement d'une pneumopathie interstitielle
WO2021252446A1 (fr) 2020-06-09 2021-12-16 United Therapeutics Corporation Promédicaments à base de fumaryle dicétopipéridine de tréprostinil
WO2022108939A1 (fr) 2020-11-17 2022-05-27 United Therapeutics Corporation Imatinib inhalé pour le domaine de l'hypertension pulmonaire
WO2022132655A1 (fr) 2020-12-14 2022-06-23 United Therapeutics Corporation Méthodes de traitement d'une maladie à l'aide de promédicaments tréprostinil
WO2022187352A1 (fr) 2021-03-03 2022-09-09 United Therapeutics Corporation Composition de poudre sèche de treprostinil et son promédicament et comprenant en outre de l'(e)-3,6-bis[4-(n-carbonyl-2-propényl)amidobutyl]-2,5-dicétopipérazine (fdkp)
US11458098B2 (en) 2019-04-29 2022-10-04 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
WO2023087345A1 (fr) * 2021-11-22 2023-05-25 兆科药业（广州）有限公司 Procédé d'atomisation pour produit à inhaler en aérosol de tréprostinil pour le traitement de l'hypertension pulmonaire
WO2023154705A1 (fr) 2022-02-08 2023-08-17 United Therapeutics Corporation Polythérapie à base de tréprostinil iloprost
WO2024155752A1 (fr) 2023-01-19 2024-07-25 United Therapeutics Corporation Analogues de tréprostinil

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2120961A1 (fr) * 2007-02-09 2009-11-25 United Therapeutics Corporation Traitement au tréprostinil d'une maladie pulmonaire interstitielle et de l'asthme
WO2009115235A1 (fr) * 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Inhibiteurs de la phosphodiestérase pour le traitement de l’hypertension pulmonaire
ES2625282T3 (es) * 2011-04-26 2017-07-19 Vectura Gmbh Administración de iloprost como bolo de aerosol
WO2014067699A1 (fr) * 2012-10-31 2014-05-08 Activaero Gmbh Administration d'iloprost à l'état d'aérosol
BR112015012547A2 (pt) * 2012-11-30 2017-07-11 Insmed Inc composições de prostaciclina e métodos de sua utilização
WO2015089105A1 (fr) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
JP2020502121A (ja) 2016-12-14 2020-01-23 レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 肺高血圧症および他の肺障害の処置のための方法および組成物
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
BR112020020127A2 (pt) * 2018-05-07 2021-01-05 Pharmosa Biopharm Inc. Composição farmacêutica, método de tratamento de uma doença respiratória e método para reduzir o efeito colateral de um treprostinil inalado na via respiratória superior
KR102259824B1 (ko) * 2018-07-24 2021-06-02 주식회사 마더스제약 보센탄을 함유한 약학 제제
CN112739679B (zh) 2018-09-18 2024-03-12 伊莱利利公司 曲前列环素的特丁胺盐
EP3750528A1 (fr) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions pour le traitement de dystrophies et de la myotonie
CN114401716A (zh) 2019-07-22 2022-04-26 纳诺米有限公司 持续释放的曲前列环素-化合物微粒组合物
CN112569210B (zh) * 2019-09-27 2023-09-15 盈科瑞（天津）创新医药研究有限公司 一种吸入用马昔腾坦溶液及其制备方法
WO2023139108A1 (fr) 2022-01-21 2023-07-27 Softhale Nv Treprostinil pour le traitement de l'hypertension pulmonaire
WO2023206444A1 (fr) * 2022-04-29 2023-11-02 兆科药业（广州）有限公司 Brume douce de tréprostinil à inhaler

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281113A (en) * 1979-07-31 1981-07-28 The Upjohn Company 2,5-Inter-o-phenylene-3,4-dinor-6,9α-epoxy-6.beta.-5-iodo-PGF1 compounds
US4306076A (en) * 1980-04-23 1981-12-15 The Upjohn Company Inter-phenylene CBA compounds
US4306075A (en) * 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4349689A (en) * 1980-12-22 1982-09-14 The Upjohn Company Methano carbacyclin analogs
US4486598A (en) * 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
US4668814A (en) * 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
US4683330A (en) * 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
US4692464A (en) * 1978-10-19 1987-09-08 Schering Aktiengesellschaft Novel prostacyclin derivatives and a process for the preparation thereof
US4708963A (en) * 1980-12-19 1987-11-24 Schering Aktiengesellschaft Novel carbacyclins, their preparation and use
US5153222A (en) * 1988-06-17 1992-10-06 Burroughs Wellcome Co. Method of treating pulmonary hypertension with benzidine prostaglandins
US5234953A (en) * 1990-05-24 1993-08-10 Burroughs Wellcome Co. Treatment of congestive heart failure
US6357671B1 (en) * 1999-02-04 2002-03-19 Siemens Elema Ab Ultrasonic nebulizer
US6469012B1 (en) * 1993-06-09 2002-10-22 Pfizer Inc Pyrazolopyrimidinones for the treatment of impotence
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US20040105819A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Respiratory drug condensation aerosols and methods of making and using them
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US7417070B2 (en) * 2003-05-22 2008-08-26 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664337A (en) 1970-04-15 1972-05-23 Bio Logics Inc Respiration assembly and methods
US4001650A (en) 1975-09-02 1977-01-04 Puritan-Bennett Corporation Method and apparatus for ultrasonic transducer protection
US4007238A (en) 1976-02-25 1977-02-08 Glenn Joseph G Nebulizer for use with IPPB equipment
US4473296A (en) 1978-05-03 1984-09-25 Ppm, Inc. System and method and apparatus for a continuous aerosol monitor (CAM) using electro-optical weighing for general aerosols
US4495944A (en) 1983-02-07 1985-01-29 Trutek Research, Inc. Inhalation therapy apparatus
US4635647A (en) 1984-09-07 1987-01-13 Choksi Pradip V Incentive spirometer employing bellows air flow sensor
NZ209900A (en) 1984-10-16 1989-08-29 Univ Auckland Automatic inhaler
US4976259A (en) 1986-12-22 1990-12-11 Mountain Medical Equipment, Inc. Ultrasonic nebulizer
US5080093A (en) 1987-07-08 1992-01-14 Vortran Medical Technology, Inc. Intermittant signal actuated nebulizer
US5322057A (en) 1987-07-08 1994-06-21 Vortran Medical Technology, Inc. Intermittent signal actuated nebulizer synchronized to operate in the exhalation phase, and its method of use
FI82808C (fi) 1987-12-31 1991-04-25 Etelae Haemeen Keuhkovammayhdi Ultraljudfinfoerdelningsanordning.
US4984158A (en) 1988-10-14 1991-01-08 Hillsman Dean Metered dose inhaler biofeedback training and evaluation system
WO1993000951A1 (fr) 1991-07-02 1993-01-21 Inhale, Inc. Procede et dispositf d'administration de medicaments en aerosol
GB2291605B (en) 1991-11-12 1996-05-01 Medix Ltd A nebuliser and nebuliser control system
US5363842A (en) 1991-12-20 1994-11-15 Circadian, Inc. Intelligent inhaler providing feedback to both patient and medical professional
FR2694215B1 (fr) 1992-07-30 1994-10-21 Dp Medical Appareil pour générer un brouillard à partir d'un liquide, notamment un médicament.
NZ256825A (en) 1992-10-16 1998-02-26 Sheiman Ultrasonic Research Fo Ultrasonic nebuliser has a tube in the upper part of a holding chamber and an ultrasonic transducer
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5752502A (en) 1993-12-16 1998-05-19 King; Russell Wayne General purpose aerosol inhalation apparatus
AU735975B2 (en) 1995-02-27 2001-07-19 Toray Industries, Inc. Remedy for pulmonary heart
US5881715A (en) 1995-07-10 1999-03-16 A & D Company, Limited Handy type atomizer
FR2746656B1 (fr) 1996-03-26 1999-05-28 System Assistance Medical Nebuliseur a capteur de pression
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
KR100638684B1 (ko) 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
DE19838711C1 (de) 1998-08-26 2000-06-21 Otto Schill Gmbh & Co Kg Inhalator zum Vernebeln von Flüssigkeiten
FR2783431B1 (fr) 1998-09-23 2001-02-02 System Assistance Medical Nebuliseur permettant de delivrer un brouillard a un patient et procede de fonctionnement d'un tel nebuliseur
DE19934582C2 (de) 1999-07-23 2003-09-18 Otto Schill Gmbh & Co Kg Aerosolerzeuger
JP4777574B2 (ja) 2000-02-11 2011-09-21 レスピロニクス・レスピラトリー・ドラッグ・デリバリー・（ユーケー）・リミテッド 薬剤投与装置
DE10022795B4 (de) 2000-05-10 2005-04-14 Pari GmbH Spezialisten für effektive Inhalation Atemgesteuertes Inhalationstherapiegerät
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
WO2002034318A2 (fr) 2000-10-20 2002-05-02 Glaxo Group Limited Inhalateur
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
CA2466214A1 (fr) 2001-09-12 2003-04-03 Ivax U.K., Ltd. Nebuliseur ultrasonore facilitant la respiration et ampoule de dose unitaire associee
US6626843B2 (en) 2001-09-28 2003-09-30 Deane Hillsman Respiratory timing and lung deflation method and device
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030192532A1 (en) 2002-04-12 2003-10-16 Hopkins Andrew David Nebulizer
US20040149282A1 (en) 2002-12-02 2004-08-05 Scott Laboratories, Inc. Respiratory monitoring systems and methods
US7726303B2 (en) 2003-02-25 2010-06-01 Hewlett-Packard Development Company, L.P. Controlled medicament ejection
JP4357230B2 (ja) * 2003-07-14 2009-11-04 帝人株式会社 酸素濃縮装置、在宅酸素療法システム
US7172557B1 (en) 2003-08-29 2007-02-06 Caldyne, Inc. Spirometer, display and method
DE602004028155D1 (de) 2003-12-16 2010-08-26 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
CA2549801C (fr) 2003-12-16 2012-10-16 United Therapeutics Corporation Amelioration des fonctions renales par le treprostinil
US7380550B2 (en) 2004-01-30 2008-06-03 Hewlett-Packard Development Company, L.P. Systems and methods for particle detection
DE102004009436A1 (de) 2004-02-24 2005-10-13 Boehringer Ingelheim International Gmbh Zerstäuber
EP1796653A2 (fr) * 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Traitement de l'hypertension pulmonaire au moyen d'iloprost inhale avec une formulation de microparticules
US7721729B2 (en) 2005-03-09 2010-05-25 Ric Investments, Llc Nebulizing drug delivery device for ventilator
CA2654492C (fr) * 2006-05-15 2017-06-27 United Therapeutics Corporation Administration de treprostinil utilisant un inhalateur a dose mesuree
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
WO2008049000A2 (fr) 2006-10-18 2008-04-24 United Therapeutics Corporation Thérapie de combinaison pour l'hypertension artérielle pulmonaire
EP2120961A1 (fr) 2007-02-09 2009-11-25 United Therapeutics Corporation Traitement au tréprostinil d'une maladie pulmonaire interstitielle et de l'asthme
CN102164487A (zh) 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
CN102421288B (zh) 2009-05-07 2015-04-22 联合治疗公司 前列环素类似物的固体剂型

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692464A (en) * 1978-10-19 1987-09-08 Schering Aktiengesellschaft Novel prostacyclin derivatives and a process for the preparation thereof
US4281113A (en) * 1979-07-31 1981-07-28 The Upjohn Company 2,5-Inter-o-phenylene-3,4-dinor-6,9α-epoxy-6.beta.-5-iodo-PGF1 compounds
US4306075A (en) * 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4306076A (en) * 1980-04-23 1981-12-15 The Upjohn Company Inter-phenylene CBA compounds
US4708963A (en) * 1980-12-19 1987-11-24 Schering Aktiengesellschaft Novel carbacyclins, their preparation and use
US4349689A (en) * 1980-12-22 1982-09-14 The Upjohn Company Methano carbacyclin analogs
US4486598A (en) * 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
US4683330A (en) * 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
US4668814A (en) * 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
US5153222A (en) * 1988-06-17 1992-10-06 Burroughs Wellcome Co. Method of treating pulmonary hypertension with benzidine prostaglandins
US5234953A (en) * 1990-05-24 1993-08-10 Burroughs Wellcome Co. Treatment of congestive heart failure
US6469012B1 (en) * 1993-06-09 2002-10-22 Pfizer Inc Pyrazolopyrimidinones for the treatment of impotence
US6357671B1 (en) * 1999-02-04 2002-03-19 Siemens Elema Ab Ultrasonic nebulizer
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6756033B2 (en) * 1999-03-18 2004-06-29 United Therapeutics Corporation Method for delivering benzindene prostaglandins by inhalation
US20040105819A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Respiratory drug condensation aerosols and methods of making and using them
US7417070B2 (en) * 2003-05-22 2008-08-26 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
US7544713B2 (en) * 2003-05-22 2009-06-09 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same

Cited By (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092599A1 (en) * 2004-04-12 2011-04-21 United Therapeutics Corporation Use of Treprostinil to treat neuropathic diabetic foot ulcers
US8563614B2 (en) 2004-04-12 2013-10-22 United Therapeutics Corporation Use of treprostinil to treat neuropathic diabetic foot ulcers
US10716793B2 (en) 2006-05-15 2020-07-21 United Therapeutics Corporation Treprostinil administration by inhalation
US20100076083A1 (en) * 2006-05-15 2010-03-25 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US11357782B2 (en) 2006-05-15 2022-06-14 United Therapeutics Corporation Treprostinil administration by inhalation
US9339507B2 (en) 2006-05-15 2016-05-17 United Therapeutics Corporation Treprostinil administration by inhalation
US9358240B2 (en) 2006-05-15 2016-06-07 United Therapeutics Corporation Treprostinil administration by inhalation
US10376525B2 (en) 2006-05-15 2019-08-13 United Therapeutics Corporation Treprostinil administration by inhalation
US9155846B2 (en) 2006-06-07 2015-10-13 United Therapeutics Corporation Dosage inhaler
US10806869B2 (en) 2006-06-07 2020-10-20 United Therapeutics Corporation Dosage inhaler
US9604901B2 (en) 2007-12-17 2017-03-28 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in Remodulin®
US10548863B2 (en) 2007-12-17 2020-02-04 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in Remodulin®
US9593066B2 (en) 2007-12-17 2017-03-14 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin®
US10478410B2 (en) 2007-12-17 2019-11-19 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in Remodulin®
US8497393B2 (en) 2007-12-17 2013-07-30 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in Remodulin®
US10322099B2 (en) 2007-12-17 2019-06-18 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin®
US8242305B2 (en) 2007-12-17 2012-08-14 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin
US8748657B2 (en) 2007-12-17 2014-06-10 United Therapeutics Corporation Process to prepare treprostinil
EP3287434A1 (fr) 2007-12-17 2018-02-28 United Therapeutics Corporation Procédé de préparation de tréprostinil, l'ingrédient actif dans le remodulin ®
US20090163738A1 (en) * 2007-12-17 2009-06-25 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin
US11723887B2 (en) 2007-12-17 2023-08-15 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in Remodulin®
US9156786B2 (en) 2007-12-17 2015-10-13 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin®
EP3002274A1 (fr) 2008-05-08 2016-04-06 United Therapeutics Corporation Monohydrate de tréprostinil
US20090281189A1 (en) * 2008-05-08 2009-11-12 United Therepeutics Corporation Treprostinil formulation
US8350079B2 (en) 2008-05-08 2013-01-08 United Therapeutics Corporation Treprostinil formulation
US20120177693A1 (en) * 2008-09-25 2012-07-12 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
US8349892B2 (en) 2009-05-07 2013-01-08 United Therapeutics Corporation Solid formulations of prostacyclin analogs
US20100282622A1 (en) * 2009-05-07 2010-11-11 United Therapeutics Corporation Solid formulations of prostacyclin analogs
US10772883B2 (en) 2009-06-12 2020-09-15 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US8609728B2 (en) 2010-03-15 2013-12-17 United Therapeutics Corporation Treatment for pulmonary hypertension
WO2011153363A1 (fr) 2010-06-03 2011-12-08 United Therapeutics Corporation Production de tréprostinil
US8481782B2 (en) 2010-06-03 2013-07-09 United Therapeutics Corporation Treprostinil production
US8940930B2 (en) 2010-06-03 2015-01-27 United Therapeutics Corporation Treprostinil production
US9611206B2 (en) 2011-03-02 2017-04-04 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
US10077225B2 (en) 2011-03-02 2018-09-18 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
US8461393B2 (en) 2011-03-02 2013-06-11 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
WO2013104317A1 (fr) 2012-01-10 2013-07-18 上海天伟生物制药有限公司 Forme cristalline d'un analogue de prostaglandine, son procédé de préparation et son utilisation
WO2013104318A1 (fr) 2012-01-10 2013-07-18 上海天伟生物制药有限公司 Forme cristalline d'un analogue de prostaglandine, son procédé de préparation et son utilisation
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10752605B2 (en) 2013-01-11 2020-08-25 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9776982B2 (en) 2013-01-11 2017-10-03 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9845305B2 (en) 2013-01-11 2017-12-19 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11505535B2 (en) 2013-01-11 2022-11-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10450290B2 (en) 2013-01-11 2019-10-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11046666B2 (en) 2013-01-11 2021-06-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11339139B2 (en) 2013-01-11 2022-05-24 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10344012B2 (en) 2013-01-11 2019-07-09 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11958822B2 (en) 2013-01-11 2024-04-16 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9822057B2 (en) 2013-03-14 2017-11-21 United Therapeutics Corporation Solid forms of treprostinil
US10167247B2 (en) 2013-03-14 2019-01-01 United Therapeutics Corporation Solid forms of treprostinil
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9988334B2 (en) 2013-03-15 2018-06-05 United Therapeutics Corporation Salts of treprostinil
US9701611B2 (en) 2013-03-15 2017-07-11 United Therapeutics Corporation Salts of treprostinil
US11236035B2 (en) 2013-03-15 2022-02-01 United Therapeutics Corporation Salts of treprostinil
US9102660B2 (en) 2013-03-25 2015-08-11 United Therapeutics Corporaiton Process of making prostacyclin compounds with linker thiol and pegylated forms
US10413513B2 (en) 2013-07-18 2019-09-17 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10010518B2 (en) 2013-10-25 2018-07-03 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
EP3808731A1 (fr) 2013-10-25 2021-04-21 Insmed Incorporated Composés de prostacycline
US10526274B2 (en) 2013-10-25 2020-01-07 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US9255064B2 (en) 2013-10-25 2016-02-09 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US11795135B2 (en) 2013-10-25 2023-10-24 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
WO2015061720A2 (fr) 2013-10-25 2015-04-30 Insmed Incorporated Composés de prostacycline, compositions en contenant et leurs procédés d'utilisation
US10995055B2 (en) 2013-10-25 2021-05-04 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
WO2015192030A1 (fr) 2014-06-13 2015-12-17 United Therapeutics Corporation Formulations de tréprostinil
WO2016064764A1 (fr) 2014-10-20 2016-04-28 United Therapeutics Corporation Synthèse d'intermédiaire pour la production de dérivés de prostacycline
US11225452B2 (en) 2014-10-20 2022-01-18 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
US10774027B2 (en) 2014-10-20 2020-09-15 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
US10196342B2 (en) 2014-10-20 2019-02-05 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
US11148997B2 (en) 2014-11-18 2021-10-19 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
WO2016088119A1 (fr) 2014-12-03 2016-06-09 Steadymed Ltd Formulations de tréprostinil exemptes de conservateur et procédés et dispositifs s'utilisant avec celles-ci
US10464877B2 (en) 2015-06-17 2019-11-05 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10246403B2 (en) 2015-06-17 2019-04-02 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10053414B2 (en) 2015-06-17 2018-08-21 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10759733B2 (en) 2015-06-17 2020-09-01 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10988435B2 (en) 2015-06-17 2021-04-27 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10464878B2 (en) 2015-06-17 2019-11-05 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11034645B2 (en) 2015-06-17 2021-06-15 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10703706B2 (en) 2015-06-17 2020-07-07 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9701616B2 (en) 2015-06-17 2017-07-11 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11866402B2 (en) 2015-06-17 2024-01-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11407707B2 (en) 2015-06-17 2022-08-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11802105B2 (en) 2015-06-17 2023-10-31 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9957220B2 (en) 2015-06-17 2018-05-01 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US20210146071A1 (en) * 2016-01-29 2021-05-20 Mannkind Corporation Dry powder inhaler
US20190321290A1 (en) * 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
CN114904100A (zh) * 2016-01-29 2022-08-16 曼金德公司 干粉吸入器
US20230098083A1 (en) * 2016-01-29 2023-03-30 Mannkind Corporation Dry powder inhaler
IL262720B2 (en) * 2016-05-05 2024-06-01 Liquidia Tech Inc Terfostinil in dry powder form for the treatment of pulmonary hypertension
US11660304B2 (en) 2016-05-05 2023-05-30 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US11744835B2 (en) * 2016-05-05 2023-09-05 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US11744836B2 (en) * 2016-05-05 2023-09-05 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US20230346799A1 (en) * 2016-05-05 2023-11-02 Liquidia Technologies, Inc. Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension
IL262720B1 (en) * 2016-05-05 2024-02-01 Liquidia Tech Inc Terfostinil in dry powder form for the treatment of pulmonary hypertension
US11712442B2 (en) 2016-05-05 2023-08-01 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US20190151332A1 (en) * 2016-05-05 2019-05-23 Liquidia Technologies, Inc. Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension
US10898494B2 (en) * 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US11672775B2 (en) 2016-09-26 2023-06-13 United Therapeutics Corporation Treprostinil prodrugs
WO2018058124A1 (fr) 2016-09-26 2018-03-29 United Therapeutics Corporation Promédicaments de tréprostinil
US11376380B2 (en) 2017-01-09 2022-07-05 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US11759425B2 (en) 2019-04-29 2023-09-19 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
US11458098B2 (en) 2019-04-29 2022-10-04 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
WO2021041320A1 (fr) 2019-08-23 2021-03-04 United Therapeutics Corporation Promédicaments de tréprostinil
US11634443B2 (en) 2019-08-23 2023-04-25 United Therapeutics Corporation Treprostinil prodrugs
US11826327B2 (en) 2020-04-17 2023-11-28 United Therapeutics Corporation Treatment for interstitial lung disease
US20210330621A1 (en) 2020-04-17 2021-10-28 United Therapeutics Corporation Treatment for interstitial lung disease
WO2021211916A1 (fr) 2020-04-17 2021-10-21 United Therapeutics Corporation Tréprostinil destiné à être utilisé dans le traitement d'une pneumopathie interstitielle
US11793780B2 (en) 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
WO2021252446A1 (fr) 2020-06-09 2021-12-16 United Therapeutics Corporation Promédicaments à base de fumaryle dicétopipéridine de tréprostinil
WO2022108939A1 (fr) 2020-11-17 2022-05-27 United Therapeutics Corporation Imatinib inhalé pour le domaine de l'hypertension pulmonaire
US11826328B2 (en) 2020-12-14 2023-11-28 United Therapeutics Corporation Stable treprostinil prodrugs
WO2022132655A1 (fr) 2020-12-14 2022-06-23 United Therapeutics Corporation Méthodes de traitement d'une maladie à l'aide de promédicaments tréprostinil
WO2022187352A1 (fr) 2021-03-03 2022-09-09 United Therapeutics Corporation Composition de poudre sèche de treprostinil et son promédicament et comprenant en outre de l'(e)-3,6-bis[4-(n-carbonyl-2-propényl)amidobutyl]-2,5-dicétopipérazine (fdkp)
WO2023087345A1 (fr) * 2021-11-22 2023-05-25 兆科药业（广州）有限公司 Procédé d'atomisation pour produit à inhaler en aérosol de tréprostinil pour le traitement de l'hypertension pulmonaire
WO2023154705A1 (fr) 2022-02-08 2023-08-17 United Therapeutics Corporation Polythérapie à base de tréprostinil iloprost
WO2024155752A1 (fr) 2023-01-19 2024-07-25 United Therapeutics Corporation Analogues de tréprostinil

Also Published As

Publication number Publication date
US20160143868A1 (en) 2016-05-26
US20100076083A1 (en) 2010-03-25
EP2026816B1 (fr) 2018-10-24
US20220323459A1 (en) 2022-10-13
US11357782B2 (en) 2022-06-14
US20120216801A1 (en) 2012-08-30
JP2016006066A (ja) 2016-01-14
CA2654492C (fr) 2017-06-27
WO2007134292A2 (fr) 2007-11-22
KR20090007797A (ko) 2009-01-20
JP2009537246A (ja) 2009-10-29
US20230062605A1 (en) 2023-03-02
US10716793B2 (en) 2020-07-21
CN101495122A (zh) 2009-07-29
JP2019112434A (ja) 2019-07-11
WO2007134292A3 (fr) 2008-01-10
EP2026816A2 (fr) 2009-02-25
US20190365778A1 (en) 2019-12-05
US9358240B2 (en) 2016-06-07
JP2014114269A (ja) 2014-06-26
US20220008436A1 (en) 2022-01-13
US10376525B2 (en) 2019-08-13
ES2707548T3 (es) 2019-04-04
JP5797376B2 (ja) 2015-10-21
US20220218720A1 (en) 2022-07-14
US9339507B2 (en) 2016-05-17
US20200171044A1 (en) 2020-06-04
KR101390579B1 (ko) 2014-05-19
CN101495122B (zh) 2011-10-05
CA2654492A1 (fr) 2007-11-22

Similar Documents

Publication Publication Date Title
US11357782B2 (en) Treprostinil administration by inhalation
EP1161234B1 (fr) Traitement de l'hypertension pulmonaire par inhalation de benzindene-prostaglandines
US10821116B2 (en) Administration of iloprost as aerosol bolus
EP2914244B1 (fr) Administration d'iloprost en aérosol

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OLSCHEWSKI, HORST;SCHMEHL, THOMAS;SEEGER, WERNER;AND OTHERS;REEL/FRAME:021148/0041;SIGNING DATES FROM 20080402 TO 20080416

Owner name: LUNG RX, INC., A WHOLLY OWNED SUBSIDIARY OF UNITED

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNITED THERAPEUTICS CORPORATION;REEL/FRAME:021148/0039

Effective date: 20080401

Owner name: LUNG RX, INC., A WHOLLY OWNED SUBSIDIARY OF UNITED

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH;REEL/FRAME:021148/0059

Effective date: 20080529

Owner name: UNITED THERAPEUTICS CORPORATION, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSCIGNO, ROBERT;RUBIN, LEWIS J.;STERRITT, CARL;REEL/FRAME:021148/0001;SIGNING DATES FROM 20070611 TO 20070718

AS Assignment

Owner name: UNITED THERAPEUTICS CORPORATION, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LUNGRX, A WHOLLY OWNED SUBSIDIARY OF UNITED THERAPEUTICS CORPORATION;REEL/FRAME:023223/0716

Effective date: 20090903

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION